Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Artemether | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Artemether. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Lumefantrine. |
| Probenecid | Probenecid may decrease the excretion rate of Dapsone which could result in a higher serum level. |
| Trimethoprim | The serum concentration of Dapsone can be increased when it is combined with Trimethoprim. |
| Mifepristone | The serum concentration of Dapsone can be increased when it is combined with Mifepristone. |
| Tetrahydrofolic acid | The therapeutic efficacy of Dapsone can be decreased when used in combination with Tetrahydrofolic acid. |
| Folic acid | The therapeutic efficacy of Dapsone can be decreased when used in combination with Folic acid. |
| Leucovorin | The therapeutic efficacy of Dapsone can be decreased when used in combination with Leucovorin. |
| (6S)-5,6,7,8-tetrahydrofolic acid | The therapeutic efficacy of Dapsone can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid. |
| Triglu-5-formyl-tetrahydrofolate | The therapeutic efficacy of Dapsone can be decreased when used in combination with Triglu-5-formyl-tetrahydrofolate. |
| Levoleucovorin | The therapeutic efficacy of Dapsone can be decreased when used in combination with Levoleucovorin. |
| 5-methyltetrahydrofolic acid | The therapeutic efficacy of Dapsone can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dapsone. |
| Thiethylperazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thiethylperazine. |
| Promazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Promazine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Prochlorperazine. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Chlorpromazine. |
| Triflupromazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Triflupromazine. |
| Fluphenazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Fluphenazine. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thioridazine. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Moricizine. |
| Trifluoperazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Trifluoperazine. |
| Perphenazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perphenazine. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Mesoridazine. |
| Acetophenazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Acetophenazine. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Promethazine. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Alimemazine. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Methotrimeprazine. |
| Periciazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Periciazine. |
| Acepromazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Acepromazine. |
| Aceprometazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Aceprometazine. |
| Pipotiazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Pipotiazine. |
| Thioproperazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thioproperazine. |
| BL-1020 | The risk or severity of QTc prolongation can be increased when Dapsone is combined with BL-1020. |
| Cyamemazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Cyamemazine. |
| Methylene blue | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Methylene blue. |
| Propiopromazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Propiopromazine. |
| Perazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perazine. |
| Butaperazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Butaperazine. |
| Chlorproethazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Chlorproethazine. |
| Thiazinam | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thiazinam. |
| Dixyrazine | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Dixyrazine. |
| Perphenazine enanthate | The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perphenazine enanthate. |
| Pyrimethamine | The risk or severity of adverse effects can be increased when Pyrimethamine is combined with Dapsone. |
| Amodiaquine | The risk or severity of adverse effects can be increased when Amodiaquine is combined with Dapsone. |
| Quinidine | The risk or severity of adverse effects can be increased when Quinidine is combined with Dapsone. |
| Quinacrine | The risk or severity of adverse effects can be increased when Quinacrine is combined with Dapsone. |
| Atovaquone | The risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone. |
| Proguanil | The risk or severity of adverse effects can be increased when Proguanil is combined with Dapsone. |
| Halofantrine | The risk or severity of adverse effects can be increased when Halofantrine is combined with Dapsone. |
| Sulfadoxine | The risk or severity of adverse effects can be increased when Sulfadoxine is combined with Dapsone. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dapsone. |
| Tafenoquine | The risk or severity of adverse effects can be increased when Tafenoquine is combined with Dapsone. |
| Artesunate | The risk or severity of adverse effects can be increased when Artesunate is combined with Dapsone. |
| Artenimol | The risk or severity of adverse effects can be increased when Artenimol is combined with Dapsone. |
| Artefenomel | The risk or severity of adverse effects can be increased when Artefenomel is combined with Dapsone. |
| Chlorproguanil | The risk or severity of adverse effects can be increased when Chlorproguanil is combined with Dapsone. |
| Mizoribine | The risk or severity of adverse effects can be increased when Mizoribine is combined with Dapsone. |
| Pyronaridine | The risk or severity of adverse effects can be increased when Pyronaridine is combined with Dapsone. |
| Artemisinin | The risk or severity of adverse effects can be increased when Artemisinin is combined with Dapsone. |
| Artemotil | The risk or severity of adverse effects can be increased when Artemotil is combined with Dapsone. |
| Piperaquine | The risk or severity of adverse effects can be increased when Piperaquine is combined with Dapsone. |
| Tetrandrine | The risk or severity of adverse effects can be increased when Tetrandrine is combined with Dapsone. |
| Cycloguanil | The risk or severity of adverse effects can be increased when Cycloguanil is combined with Dapsone. |
| Butalbital | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Butalbital. |
| Phenytoin | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Phenytoin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Lidocaine. |
| Acetaminophen | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Acetaminophen. |
| Nitroprusside | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitroprusside. |
| Sulfadiazine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfadiazine. |
| Nitric Oxide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitric Oxide. |
| Quinine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Quinine. |
| Celecoxib | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Celecoxib. |
| Flutamide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Flutamide. |
| Chloroquine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Chloroquine. |
| Nitrofurantoin | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitrofurantoin. |
| Nitroglycerin | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitroglycerin. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Prilocaine. |
| Isosorbide dinitrate | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Isosorbide dinitrate. |
| Sulfamethoxazole | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfamethoxazole. |
| Isosorbide mononitrate | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Isosorbide mononitrate. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Benzocaine. |
| Primaquine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Primaquine. |
| Phenobarbital | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Phenobarbital. |
| Zopiclone | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Zopiclone. |
| Metoclopramide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Metoclopramide. |
| Antipyrine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Antipyrine. |
| Phenazopyridine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Phenazopyridine. |
| Amyl Nitrite | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Amyl Nitrite. |
| Isometheptene | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Isometheptene. |
| Mafenide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Mafenide. |
| Nitrous oxide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitrous oxide. |
| Cyclophosphamide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Cyclophosphamide. |
| Ifosfamide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Ifosfamide. |
| Sulfasalazine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfasalazine. |
| Sulfanilamide | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfanilamide. |
| Sulfapyridine | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfapyridine. |
| Valproic acid | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Valproic acid. |
| Rasburicase | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Rasburicase. |
| Aminosalicylic acid | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Aminosalicylic acid. |